Trial Profile
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of Tucatinib (MK-7119) in China Participants With HER2+ Advanced Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 16 Apr 2024 Planned primary completion date changed from 29 Dec 2023 to 28 Jan 2025.
- 21 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2022 Status changed from not yet recruiting to recruiting.